Periprocedural Drug Therapy in Carotid Artery Stenting: The Need for More Evidence

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8089, USA.
Vascular (Impact Factor: 0.8). 12/2008; 16(6):303-9. DOI: 10.2310/6670.2008.00081
Source: PubMed


Carotid artery stenting (CAS) is a widely accepted alternative for patients at high risk for carotid endarterectomy (CEA). However, the role, indications, and evidence for many pharmacologic agents that are used adjunctively in the periprocedural setting have not been established. Several drugs are commonly used before, during, and after CAS, but their uses have not been standardized. Large prospective cohort studies with good validity or randomized trials are needed to demonstrate efficacy, predict outcome, and determine the optimal use of these medications in patients undergoing CAS to improve patient care and obtain optimal outcomes. Several conclusions can be made: (1) dual-antiplatelet therapy (aspirin and clopidogrel) is commonly used for CAS; (2) the most commonly used regimen is aspirin 325 mg and clopidogrel 75 mg per day, but the optimal time of therapy is unknown; and (3) the dose and regimen of other agents used for CAS are not established.

3 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Carotid artery stenting (CAS) prior to open-heart surgery may be a useful approach to minimise the risk of neurologic events in patients undergoing aortic valve replacement (AVR). All patients referred for carotid intervention at our institution between 1998 and 2005 with concomitant severe aortic stenosis (AS) (aortic valve area <1.0 cm2) were included. Data were obtained prospectively and confirmed by chart review. The primary endpoint was all-cause mortality at 30-days after CAS or AVR. Secondary endpoints included incidence of stroke, transient ischaemic attack (TIA), and myocardial infarction (MI) at 30-days after CAS or AVR. Patients were followed-up at 30-days, six months, and annually thereafter. Of the 829 patients who underwent CAS, 52 had severe AS. Carotid stenting in 28 (54%) of the patients was attempted using embolic protection devices. Three patients (6%) died <30 days after carotid stenting, and two (4%) died >30 days after carotid stenting but prior to aortic valve replacement. At one year after CAS, a total of nine patients had died. There were a total of 19 deaths (37%) over a median follow-up of 3.8 years. One patient (2%) suffered a TIA during carotid stenting; at 30-days and 1-year there were no strokes in the CAS group. There were no MI's. AVR was performed in 29 patients (56%), and at 30-days and 1-year there were no strokes or deaths noted in those patients. In patients with severe AS, CAS can be accomplished effectively and with a low rate of stroke, MI, and death.
    EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 09/2010; 6(4):492-7. DOI:10.4244/EIJ30V6I4A82 · 3.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing data suggest that statins can significantly decrease cardiovascular and cerebrovascular events due to a plaque stabilization effect. However, the benefit of statins in patients undergoing carotid angioplasty and stenting (CAS) for carotid stenosis is not well defined. The aim of this study was to investigate whether statins use was associated with decreased perioperative and late risks of stroke, mortality, and restenosis in patients undergoing CAS. All patients undergoing CAS for primary carotid stenosis from 2004 to 2009 were reviewed. The independent association of statins and perioperative morbidity was assessed using multivariable analysis. Survival curves and Cox regression models were used to assess late morbidity and restenosis. Propensity score adjustment was employed. A total of 1083 consecutive CAS were performed (29% females, mean age 71.5 years; 24.7% symptomatic); 465 (43%) were on statins medication before treatment that was not discontinued at discharge. Statins use was associated with a reduction of perioperative stroke and death (odds ratio [OR] 0.327, 95% confidence interval [CI] 0.13-0.80, P = .016) according to multivariable analysis. Statins effect was more significant in reducing stroke and death in symptomatic patients (OR 0.13; P = .032) and in males (OR 0.27, P = .01). At 5 years, survival (87.2% vs 78.3%; P = .009) and ischemic stroke-free interval (88.9% vs 99.7%; P = .02) rates were higher in the statins group of patients. Adjusting for propensity score and covariates in Cox regression analyses, statins use was independently associated with reduced long-term mortality risk (HR 0.56, 95% CI 0.32-0.97; P = .039) and borderline associated with decreased late ischemic stroke risk (HR 0.14; 95% CI 0.018-1.08, P = .059). There was no effect on restenosis rates. These data suggest that statins use is associated with decreased perioperative and late ischemic strokes risk and reduced mortality rates in patients undergoing CAS. Statins therapy should be considered part of the best medical treatment in current CAS practice.
    Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 10/2010; 53(1):71-9; discussion 79. DOI:10.1016/j.jvs.2010.08.024 · 3.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic cerebrovascular injury (TCVI) is present in approximately 1% of all blunt force trauma patients and is associated with injuries such as head and cervical spine injuries and thoracic trauma. Increased recognition of patients with TCVI in the past quarter century has been because of aggressive screening protocols and noninvasive imaging with computed tomography angiography. Extracranial carotid and vertebral artery injuries demonstrate a spectrum of severity, from intimal disruption to traumatic aneurysm formation or vessel occlusion. The most common intracranial arterial injuries are carotid-cavernous fistulae and traumatic aneurysms. Data on the long-term natural history of TCVI are limited, and management of patients with TCVI is controversial. Although antithrombotic medical therapy is associated with improved neurological outcomes, the optimal medication regimen is not yet established. Endovascular techniques have become more popular than surgery for the treatment of TCVI; endovascular options include stenting of dissections, intra-arterial thrombolysis for acute ischemic stroke caused by trauma, and embolization of traumatic aneurysms.
    Neurosurgery 11/2010; 68(2):517-30; discussion 530. DOI:10.1227/NEU.0b013e3181fe2fda · 3.62 Impact Factor
Show more

Similar Publications